Changes in the functional state of the epithelium of the proximal renal tubules in individuals with dyslipidemia associated with obesity complications of type 2 diabetes, when taking simvastatin, in the aspect of cardio-renal syndrome

Abstract

Goal. To assess the change in the level of activity of renal organ-specific enzymes neutral α-glucosidase (NAG) and L-alanine aminopeptidase (PAP) in patients with dyslipidemia on the background of obesity complicated by type 2 diabetes mellitus (DM2) during simvastatin therapy for three months.
Materials and methods. 86 people were studied. 30 subjects were a control group of healthy individuals, 14 men and 16 women. The comparison group consisted of 27 subjects-11 men and 16 women. The main group-14 subjects were persons suffering from type 2 diabetes, of which 7 are male and 7 are female, and 15 subjects without type 2 diabetes, 5 men and 10 women. Patients in the main group took simvastatin at a daily dose of 20 mg.
Results. According to the data obtained the level of activity of NAG in the comparison group 1,75 ± 0,16 nkat/mmol creatinine 1 urine, patients of the main group without T2DM of 22.75 ± 5,97 nkat/1 mmol of creatinine and urine of the patients with the presence of T2DM 17,27 ± 2,47 nkat/1 mmol of urine creatinine was significantly higher than in patients of control group 1,34 ± 0,14 nkat/1 mmol of urine creatinine. Similarly, the level of CLUTCHES in the comparison group was 1.17 ± 0,21 nkat/mmol creatinine 1 urine, patients of the main group without T2DM accounting period 16.57 ± 3,68 nkat/1 mmol of creatinine and urine of the patients of the main group with T2DM 22,91 ± 4,26 nkat/1 mmol of urine creatinine significantly higher in the investigated control group 0,72 ± 0,09 nkat/1 mmol of urine creatinine. After 3 months of taking simvastatin at a dose of 20 mg per day the study group patients, a decrease in activity as the NAGA of 13.17 ± 2,71 nkat/mmol creatinine 1 urine and PAWS of 9.4 ± 1,62 nkat/1 mmol of urine creatinine in the urine of patients without T2DM, the reduction in the activity of the CLUTCHES of 14.9 ± 3,72 nkat/1 mmol of urine creatinine and increased activity of NAG was 26.7 ± 6,03 in patients with T2DM.
Conclusion. Simvastatin administration in patients with dyslipidemia on the background of obesity, without SD2 reduces the level of activity of NAG and PAWS, in patients with SD2, there is a decrease in the activity of PAWS, while increasing the concentration of NAG in the urine